AgeneBio Announces Two NIH Grant Awards to Advance its Therapeutic Pipeline to Combat Progression of Alzheimer’s Disease

– NIH awards an expected $16 million to support Phase 3 pivotal clinical trial of AGB-101, a once-a-day treatment to slow progression in Mild Cognitive Impairment due to Alzheimer’s disease. – NIH awards follow on funding from the Blueprint Neurotherapeutics (BPN) Network Program to support development of GABA-A a5 small molecule program targeting hippocampal overactivity.…